IndiaLATAM drive earnings

Company
11 Mar 2024
5 Min read 
  • Torrent Pharma's 3QFY24 results showed a healthy EBITDA growth driven by domestic formulation and LatAm segments.
  •  The lack of approvals and marginal price erosion in the US affected overall performance.
  •  The company plans to expand its branded generics segment in DF/LATAM and launch products in the US generics segment.
  •  Sales in India, Germany, and Brazil showed growth, while US sales declined.
  •  The company expects a 30% earnings CAGR over FY24-25.
  •  The stock is rated as Neutral with a target price of INR2,540.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority